Clinical Trials Arena on MSN

BMS delays Alzheimer’s readout for Cobenfy over 'site irregularities'

B ristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of Cobenfy (xanomeline/trospium ...
BioSpace

BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study

Analysts had noted "unease" from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a "significant ...

A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why.

Bristol Myers’ stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer’s treatment, even ...
NBC 10 Philadelphia

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

In an interview, company executives said each treatment use they are studying for Cobenfy has multibillion-dollar potential, including Alzheimer's disease psychosis, Alzheimer's agitation and ...
Nasdaq

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?

While the year started on a positive note and the stock touched a 52-week high of $63.33 on March 11, it has been on a downward trend thereafter and touched a 52-week low of $42.96 on July 31.
NBC New York

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb believes Alzheimer's is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In an ...